325 related articles for article (PubMed ID: 30220082)
1. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
Click ZR; Seddon AN; Bae YR; Fisher JD; Ogunniyi A
Pharmacotherapy; 2018 Nov; 38(11):1143-1154. PubMed ID: 30220082
[TBL] [Abstract][Full Text] [Related]
2. Incorporating newer agents in the treatment of acute myeloid leukemia.
Raj RV; Abedin SM; Atallah E
Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
[TBL] [Abstract][Full Text] [Related]
3. New and emerging therapies for acute myeloid leukaemia.
Davis JR; Benjamin DJ; Jonas BA
J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
[TBL] [Abstract][Full Text] [Related]
4. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP; Stahl M; Zeidan AM
Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
Krauss AC; Gao X; Li L; Manning ML; Patel P; Fu W; Janoria KG; Gieser G; Bateman DA; Przepiorka D; Shen YL; Shord SS; Sheth CM; Banerjee A; Liu J; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2019 May; 25(9):2685-2690. PubMed ID: 30541745
[TBL] [Abstract][Full Text] [Related]
6. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
7. The role of targeted therapy in the management of patients with AML.
Perl AE
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):54-65. PubMed ID: 29222237
[TBL] [Abstract][Full Text] [Related]
8. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
9. Progress and predictions: AML in 2018.
Rowe JM
Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
[TBL] [Abstract][Full Text] [Related]
10. Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia.
Tran AA; Miljković M; Prasad V
Leuk Res; 2020 Sep; 96():106420. PubMed ID: 32712431
[TBL] [Abstract][Full Text] [Related]
11. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
13. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
15. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
Yamauchi T
Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
[TBL] [Abstract][Full Text] [Related]
16. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
17. First Approved Kinase Inhibitor for AML.
Rasko JEJ; Hughes TP
Cell; 2017 Nov; 171(5):981. PubMed ID: 29149610
[TBL] [Abstract][Full Text] [Related]
18. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Talati C; Sweet K
Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
[TBL] [Abstract][Full Text] [Related]
19. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
Talati C; Lancet JE
Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
[TBL] [Abstract][Full Text] [Related]
20. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
Goldsmith SR; Lovell AR; Schroeder MA
Drugs Today (Barc); 2019 Sep; 55(9):545-562. PubMed ID: 31584572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
